Apellis Pharmaceuticals, Inc.·4

Jun 11, 4:27 PM ET

Boucher Kelley 4

4 · Apellis Pharmaceuticals, Inc. · Filed Jun 11, 2025

Insider Transaction Report

Form 4
Period: 2025-06-09
Boucher Kelley
Chief People Officer
Transactions
  • Award

    Common Stock

    2025-06-09+45,09567,182 total
  • Award

    Stock Option (Right to Buy)

    2025-06-09$19.39/sh+67,396$1,306,80867,396 total
    Exercise: $19.39Exp: 2035-06-09Common Stock (67,396 underlying)
Footnotes (2)
  • [F1]This represents an award of Restricted Stock Units granted June 9, 2025, that vests annually from grant date over a four-year period subject to continued service.
  • [F2]This represents a stock option award granted June 9, 2025 that vests over a four-year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT